Fennec Pharmaceuticals Inc (RV41 F) stock market data APIs
€6.1315
0.06(1%)
as of January 20, 2026
Try our APIs with
free plan!
Fennec Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Prev. Close
6.1315
Open
6.1935
High
6.2332
Low
6.1204
52 wk Range
4.3-8.25
Market Cap
215 M
Shares Outstanding
34 153 K
Revenue
38 790 K
EPS
-0.15
Beta
0.776
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Fennec Pharmaceuticals Inc data using free add-ons & libraries
Get Fennec Pharmaceuticals Inc Fundamental Data
Fennec Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 38 790 K
- EBITDA: -4 327 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-10
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fennec Pharmaceuticals Inc News
New
Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update
Fennec Pharmaceuticals Inc. ~ Growing Physician Awareness and Usage of PEDMARK® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief...
Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
Fennec Pharmaceuticals Inc. RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, ...
Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Inc. RESEARCH TRIANGLE PARK, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees l...
Retail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as well
Key Insights Significant control over Fennec Pharmaceuticals by retail investors implies that the general public has more power to influence management and governance-related decisions The top 7 shar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
